Sutro reads the farletuzumab tea leaves
Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.
Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.